Welcome to Awesome Blog Design perfect blog
Business, Healthcare

EOM Pharmaceuticals announces its pre-IND meeting request with U.S. FDA to evaluate plans for a Phase 2 clinical trial of its investigational dual-acting, broad-spectrum immunomodulator in COVID-19 patients

EOM developing IND for evaluating EOM613 safety and efficacy to treat the most severe effects of COVID-19, including ARDS MONTVALE, N.J.–(BUSINESS WIRE)–EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, today announced it has filed a pre-Investigational New Drug Application (pre-IND) meeting request